US20200299783A1
University of Texas System
Provided herein is a molecular signature that delineates response to ibrutinib and its use in predicting responsiveness to ibrutinib for lymphoma patients, and in particular for mantle cell lymphoma patients. Also provided are methods of treating a patient that is predicted to be ibrutinib- …